Patient Derived Xenograft Models Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Patient Derived Xenograft Models Market is segmented by Type (Mice Model and Rats Model), Tumor Type (Gastrointestinal Tumor Model, Gynecological Tumor Model, Respiratory Tumor Model, and Other Tumor Model), End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, and Others), and Geography (North America, Europe, Asia-Pacific, Rest of the World). The report offers the value (in USD million) for the above segments.

Patient Derived Xenograft Models Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Patient Derived Xenograft Models Market Size

Patient Derived Xenograft Models Market Summary
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
CAGR 12.50 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration High

Major Players

Patient Derived Xenograft Models Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Global Patient Derived Xenograft Models Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Patient Derived Xenograft Models Market Analysis

The Global Patient Derived Xenograft Models Market is expected to register a CAGR of 12.5% during the forecast period.

During the COVID-19 pandemic, cancer research was halted as the majority of studies were focused on developing drugs for COVID-19. However, post-pandemic, the majority of the focus of researchers has been on developing innovative therapies for cancer. This is expected to support the growth of the industry.

The rising cases of cancer, rising research and development activities in the pharmaceutical industry, and continuous support for cancer research from the public, as well as the private sector, are the major factors driving the market growth. For instance, according to the GLOBOCAN Report 2020, globally, around 19,292,789 new cancer cases have been reported, and 9,958,133 reported cancer deaths. The majorly affecting cancers are breast cancer, lung cancer, colorectum cancer, and prostate cancer.

In addition, the increasing research using mouse models for drug discovery for cancer is also anticipated to contribute to market growth. For example, as per the article published in April 2022 by Oncoimmunology, the researchers utilized the Diversity Outbred (DO) and Collaborative Cross (CC) mouse models to investigate the outcomes of the immune checkpoint inhibitors (ICI) for a variety of malignancies. The researchers of the study purchased the DO mice models from the Jackson Laboratory and all CC mice from the Systems Genetics Core Facility at the University of North Carolina. Such adoption of mice models in cancer research is expected to contribute to market growth over the forecast period.

However, the high cost of personalized patient-derived xenograft models and stringent regulations towards the use of animal models are likely to impede market growth over the forecast period.

Patient Derived Xenograft Models Industry Overview

The patient-derived xenograft market is consolidated in nature due to the presence of a few key companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold significant market shares and are well known, including Champions Oncology, Inc., Crown Bioscience, Inc., Charles River Laboratories, Inc., EPO Berlin-Buch GmbH, Hera BioLabs, Oncodesign, Pharmatest Services Ltd, Urolead and Xentech among others.

Patient Derived Xenograft Models Market Leaders

  1. Champions Oncology, Inc.

  2. Crown Bioscience, Inc.

  3. Charles River Laboratories, Inc.

  4. EPO Berlin-Buch GmbH

  5. Oncodesign

  6. *Disclaimer: Major Players sorted in no particular order
Patient Derived Xenograft Models Market
Need More Details on Market Players and Competiters?
Download PDF

Patient Derived Xenograft Models Market News

  • July 2022: GemPharmatech (GemPharmatech Co., Ltd.) announced that it has entered into a strategic license agreement with Charles River Laboratories, Inc. for exclusive distribution of its next-generation NOD CRISPR Prkdc Il2r gamma (NCG) mouse lines in North America. Charles River will establish foundation colonies with models to be commercially available beginning in 2023.
  • April 2022: The research group of Professor Kamimura at Niigata University established a novel pancreatic carcinogenesis model in wild-type rats utilizing the pancreas-targeted selective hydrodynamic gene delivery method.

Patient Derived Xenograft Models Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Cases of Cancer
    • 4.2.2 Rising R&D Activities in the Pharmaceutical Industry
    • 4.2.3 Continuous Support for Cancer Research From Public as Well as Private Sector
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Personalized Patient Derived Xenograft Models
    • 4.3.2 Stringent Regulations Towards Use of Animals Models
  • 4.4 Porter Five Forces
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD Million)

  • 5.1 By Type
    • 5.1.1 Mice Model
    • 5.1.2 Rats Model
  • 5.2 By Tumor Type
    • 5.2.1 Gastrointestinal Tumor Model
    • 5.2.2 Gynecological Tumor Model
    • 5.2.3 Respiratory Tumor Model
    • 5.2.4 Other Tumor Model
  • 5.3 By End User
    • 5.3.1 Pharmaceutical & Biotechnology Companies
    • 5.3.2 Academic & Research Institutions
    • 5.3.3 Others
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Rest of the World

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Champions Oncology, Inc.
    • 6.1.2 Charles River Laboratories, Inc.
    • 6.1.3 Crown Bioscience, Inc.
    • 6.1.4 EPO Berlin-Buch GmbH
    • 6.1.5 Hera BioLabs
    • 6.1.6 Oncodesign
    • 6.1.7 Pharmatest Services Ltd
    • 6.1.8 Urolead
    • 6.1.9 Xentech
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Patient Derived Xenograft Models Industry Segmentation

As per the scope of the report, patient-derived xenografts (PDX) are models in which cancerous tissue from a patient's tumor is implanted directly into humanized mice or rats. The xenograft model offers fast testing of novel compounds on cancer cell lines. The Patient Derived Xenograft Models Market is Segmented By Type (Mice Model, Rats Model), Tumor Type (Gastrointestinal Tumor Model, Gynecological Tumor Model, Respiratory Tumor Model, and Other Tumor Model), End User (Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, and Others), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and Rest of the World). The report offers the value (in USD million) for the above segments.

By Type Mice Model
Rats Model
By Tumor Type Gastrointestinal Tumor Model
Gynecological Tumor Model
Respiratory Tumor Model
Other Tumor Model
By End User Pharmaceutical & Biotechnology Companies
Academic & Research Institutions
Others
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Rest of the World
Need A Different Region or Segment?
Customize Now

Patient Derived Xenograft Models Market Research FAQs

What is the current Global Patient Derived Xenograft Models Market size?

The Global Patient Derived Xenograft Models Market is projected to register a CAGR of 12.5% during the forecast period (2025-2030)

Who are the key players in Global Patient Derived Xenograft Models Market?

Champions Oncology, Inc., Crown Bioscience, Inc., Charles River Laboratories, Inc., EPO Berlin-Buch GmbH and Oncodesign are the major companies operating in the Global Patient Derived Xenograft Models Market.

Which is the fastest growing region in Global Patient Derived Xenograft Models Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Global Patient Derived Xenograft Models Market?

In 2025, the North America accounts for the largest market share in Global Patient Derived Xenograft Models Market.

What years does this Global Patient Derived Xenograft Models Market cover?

The report covers the Global Patient Derived Xenograft Models Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Global Patient Derived Xenograft Models Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Global Patient Derived Xenograft Models Industry Report

Statistics for the 2025 Global Patient Derived Xenograft Models market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global Patient Derived Xenograft Models analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.